Lymphoma News

In a scientific statement, the American Heart Association issued guidance on the epidemiology, diagnosis and management of cancer therapy-induced hypertension.

NEW ORLEANS — Cost efficacy of polatuzumab vedotin added to traditional treatments for diffuse large B-cell lymphoma in the front-line requires long-term PFS data, according to a poster presented at ASH Annual Meeting and Exhibition.

NEW ORLEANS — Black adolescent and young adult patients with diffuse large B-cell lymphoma experienced worse overall outcomes in terms of mortality rate and survival compared with other races, according to a study.

NEW ORLEANS — Mosunetuzumab with polatuzumab vedotin showed efficacy in patients with diffuse large B-cell lymphoma who are younger and older than 65 years, according to research presented at the ASH Annual Meeting and Exhibition.

NEW ORLEANS — Patients diagnosed with lymphoma were likely to experience anxiety and depression, lowering overall quality of life, according to a presenter at ASH Annual Meeting and Exhibition.

NEW ORLEANS — Breakthrough COVID infection rates in patients with hematologic malignancies did not correlate with anti-spike antibody levels, suggesting mRNA vaccines may have lost efficacy against the omicron strain, according to a study.

A year ago, American Red Cross declared the first-ever national blood crisis amid a surge in the omicron variant of COVID-19.

NEW ORLEANS — Induction with brentuximab vedotin plus AVD chemotherapy followed by nivolumab consolidation exhibited encouraging activity among previously untreated patients with limited-stage non-bulky Hodgkin lymphoma, according to study results.

A risk model based on low-pass whole-genome sequencing of cell-free DNA predicted which patients are more likely to respond to chimeric antigen receptor T-cell therapy for large B-cell lymphoma, study results showed.

Posoleucel demonstrated encouraging efficacy against common viral infections among patients who underwent allogeneic hematopoietic stem cell transplantation, according to phase 2 study results published in Clinical Cancer Research.